Ladprao General Hospital Public Company Limited(LPH.BK)
No price history available.
Key financial summary
Financials in THB| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | THBm | 1,801 | 2,501 | 2,417 | 2,233 | 2,399 | 2,585 | N/A | N/A |
| Operating profit | THBm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | THBm | 143 | 465 | 323 | 64 | 78 | 197 | N/A | N/A |
| EPS reported | THB | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | THB | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | THB | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | THB | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | THBm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | THBm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | THBm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | THB | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | THB | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in THB| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Ladprao General Hospital Public Company Limited, including its subsidiaries, functions as a prominent healthcare provider in Thailand, primarily through the operation of the private Ladprao General Hospital. This facility offers an extensive range of medical specialties, such as neurology, cardiology, hypertension management, dentistry, hemodialysis, pediatrics, refractive eye surgery, women's health, aesthetic and dermatological services, laser treatments, and ear, nose, and throat care. The hospital also hosts specialized centers for health screenings, gastroenterology, hepatology, orthopedics, physical therapy, and rehabilitation. Expanding beyond direct patient care, the company delivers scientific analytical and diagnostic services for industries including food, agriculture, pharmaceuticals, and environmental protection. It further conducts instrument calibration, quality inspections, and provides certifications that adhere to stringent quality systems and international benchmarks. Other ventures include hospital management and consulting, mobile health check-ups, and professional nursing services for industrial sites and other organizations. Moreover, the company actively researches, develops, cultivates, and distributes herbal products with medicinal benefits. Established in 1990, Ladprao General Hospital Public Company Limited is headquartered in Bangkok, Thailand.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Ladprao General Hospital Public Company Limited (LPH.BK)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Ladprao General Hospital Public Company Limited, including its subsidiaries, functions as a prominent healthcare provider in Thailand, primarily through the operation of the private Ladprao General Hospital. This facility offers an extensive range of medical specialties, such as neurology, cardiology, hypertension management, dentistry, hemodialysis, pediatrics, refractive eye surgery, women's health, aesthetic and dermatological services, laser treatments, and ear, nose, and throat care. The hospital also hosts specialized centers for health screenings, gastroenterology, hepatology, orthopedics, physical therapy, and rehabilitation. Expanding beyond direct patient care, the company delivers scientific analytical and diagnostic services for industries including food, agriculture, pharmaceuticals, and environmental protection. It further conducts instrument calibration, quality inspections, and provides certifications that adhere to stringent quality systems and international benchmarks. Other ventures include hospital management and consulting, mobile health check-ups, and professional nursing services for industrial sites and other organizations. Moreover, the company actively researches, develops, cultivates, and distributes herbal products with medicinal benefits. Established in 1990, Ladprao General Hospital Public Company Limited is headquartered in Bangkok, Thailand.